Tuberous Sclerosis Complex Management
Introduction to TSC
- The American College of Physicians recommends that all patients with Tuberous Sclerosis Complex (TSC) receive coordinated care from a multidisciplinary team including neurology, nephrology, pulmonology, dermatology, and other specialties to reduce mortality and morbidity 2, 3.
Multidisciplinary Approach
- The European Society of Medical Oncology suggests that all TSC patients should be referred to a specialist center with a multidisciplinary team for coordinated care 2.
- Patients should have regular follow-up with specialists relevant to their specific symptoms at least once a year 2.
Kidney Surveillance Protocol
- The National Institute for Health and Care Excellence recommends regular kidney surveillance from the time of diagnosis, as kidney disease is a common cause of death in adults with TSC 2, 3, 1.
- Kidney surveillance should start at diagnosis, even in young children, as cysts and angiomyolipomas can develop in the first months of life 2, 3, 1.
TSC-Associated Renal Cell Carcinoma Management
- The American Urological Association notes that there is no randomized controlled trial to support different treatment approaches for TSC-associated renal cell carcinoma (RCC) compared to sporadic RCC 4, 5.
- TSC-associated RCC appears to have different histopathological patterns and a more indolent course than sporadic RCC, with only rare reports of mortality 4, 5.
Surgical Approach
- The European Association of Urology recommends a nephron-sparing approach for surgical management of TSC-associated RCC, based on multidisciplinary evaluation (Level B, strong) 6.
- For cases without suspicion of malignancy, tumor enucleation is preferred over marginal tumor resection (Level C, moderate) 6.
Angiomyolipoma Management
- The American College of Radiology recommends radiologic or surgical intervention for angiomyolipoma bleeding that compromises hemodynamics (Level X, strong) 6.
- For cases requiring intervention, radiologic intervention is the first-line approach, if available (Level X, strong) 6.
mTOR Inhibitor Therapy
- The National Kidney Foundation suggests that mTOR inhibitors (such as everolimus) are effective in reducing the size of angiomyolipomas and slowing disease progression 3.
- Proteinuria may develop or worsen during mTOR inhibitor therapy, requiring regular monitoring 2, 3.
Post-Kidney Transplant Management
- The European Society of Organ Transplantation recommends against routine nephrectomy in TSC patients who have undergone kidney transplant (Level X, strong) 6.
- mTOR inhibitor-based immunosuppressive regimens should be considered for TSC patients with known responsiveness to mTOR inhibition after kidney transplant 6, 2.